Dec 11, 2018
Alligator Bioscience Starts Clinical Phase I Study With ATOR-1015
Nov 09, 2018
Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting
Nov 07, 2018
Alligator Bioscience to Receive Million-dollar Payments - AbClon Partner Exercises Option
Oct 30, 2018
Alligator Bioscience Expands Pipeline: Preclinical Development Initiated for the Candidate Drug ATOR-1144
Oct 26, 2018
Alligator Bioscience AB Interim Report January-September 2018
Oct 05, 2018
Alligator Bioscience Receives Government Research Grant
Sep 28, 2018
New Preclinical Data Support Good Tolerability Properties for the 4-1BB Antibody ATOR-1017
Jul 12, 2018
Alligator Bioscience AB Interim Report January-June 2018
Jun 21, 2018
Alligator Bioscience's ATOR-1017 Strongly Activates Both T cells and NK Cells, Important for the Effective Eradication of Tumor Cells
May 29, 2018
Alligator Bioscience Capital Markets Day Today on May, 29
May 16, 2018
Invitation to Alligator Bioscience Capital Markets Day in Stockholm on May 29, 2018
Apr 26, 2018
Alligator Bioscience AB Interim Report January-March 2018
Apr 17, 2018
Alligator Bioscience Presents ATOR-1015 Preclinical Data at the AACR Annual Meeting 2018 Confirming Localized Tumor Activation
Apr 05, 2018
Alligator Bioscience Presents at the H.C. Wainwright Annual Global Life Sciences Conference
Mar 22, 2018
Alligator Bioscience's Annual Report 2017 Published
Jan 25, 2018
Alligator Bioscience Contracts Theradex Oncology as Clinical CRO for the Upcoming ATOR-1015 Phase I Study
Jan 18, 2018
Alligator Bioscience Appoints New VP Business Development
Jan 04, 2018
Alligator Bioscience to Present at the 10th Annual Biotech Showcase Conference
Nov 21, 2017
Alligator Bioscience AB Presents at Redeye Life Science Seminar 24 November 2017
Nov 07, 2017
Results From Alligator Bioscience's Clinical Phase I Study Support Further Clinical Development of ADC-1013